Respiratory disease is a main feature of severe COVID-19, and the potential of IL-6 receptor blockade to increase risk of pneumonia warrants vigilance and caution in their application to treat COVID-19
Background: Cancer and transplant patients with COVID-19 have a higher risk of developing severe and...
The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid develop...
Introduction: To date, only corticosteroids and inter-leukin-6 (IL-6) inhibitors have been shown to ...
The inflammatory cytokine interleukin-6 (IL-6) is central to orchestrating the immune system. The pa...
Background Sepsis is characterised by dysregulated, life-threatening immune responses, which are tho...
There is controversy whether IL-6 (receptor) antagonists are beneficial in treating COVID-19 patient...
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a dysregulated hy...
Abstract Purpose COVID-19 is characterized by dysregulated immune response, respiratory failure and ...
International audienceBackground Our objective was to determine whether anti-interleukin (IL)-6 rece...
Cytokine release syndrome (CRS) is known to be a factor in morbidity and mortality associated with a...
BACKGROUND: Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interl...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications a...
Introduction: Preliminary studies showed that coronavirus disease 2019 (COVID-19) disrupts body immu...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications a...
Interleukin-6 (IL-6), known as an inflammatory cytokine, can be involved in many innate and adaptive...
Background: Cancer and transplant patients with COVID-19 have a higher risk of developing severe and...
The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid develop...
Introduction: To date, only corticosteroids and inter-leukin-6 (IL-6) inhibitors have been shown to ...
The inflammatory cytokine interleukin-6 (IL-6) is central to orchestrating the immune system. The pa...
Background Sepsis is characterised by dysregulated, life-threatening immune responses, which are tho...
There is controversy whether IL-6 (receptor) antagonists are beneficial in treating COVID-19 patient...
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a dysregulated hy...
Abstract Purpose COVID-19 is characterized by dysregulated immune response, respiratory failure and ...
International audienceBackground Our objective was to determine whether anti-interleukin (IL)-6 rece...
Cytokine release syndrome (CRS) is known to be a factor in morbidity and mortality associated with a...
BACKGROUND: Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interl...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications a...
Introduction: Preliminary studies showed that coronavirus disease 2019 (COVID-19) disrupts body immu...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications a...
Interleukin-6 (IL-6), known as an inflammatory cytokine, can be involved in many innate and adaptive...
Background: Cancer and transplant patients with COVID-19 have a higher risk of developing severe and...
The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid develop...
Introduction: To date, only corticosteroids and inter-leukin-6 (IL-6) inhibitors have been shown to ...
DOI
Add to ORKG